Altaris Completes $18.50/Share Take-Private of Simulations Plus…

Event summary

Altaris completed its acquisition of Simulations Plus for $18.50 per share in cash, delisting the company from Nasdaq.
Simulations Plus is being merged with Altaris portfolio company Chemical Computing Group to create a broader drug discovery and development platform.
The combined entity will operate under separate brands but leverage complementary technologies and customer relationships.
Altaris manages $10 billion in equity capital and has invested in over 50 healthcare companies since 2003.

The big picture

This acquisition reflects the growing trend of private equity firms consolidating specialized healthcare technology companies to create scalable platforms. With $10 billion in assets under management, Altaris is positioning the combined entity to dominate the drug discovery and development software market. The deal highlights the increasing importance of AI and modeling in accelerating biopharmaceutical innovation.

What we're watching

Integration Challenges: How the combined entity will manage cultural and operational differences between Simulations Plus and Chemical Computing Group.
Innovation Acceleration: Whether the merger will lead to faster development of AI-driven drug discovery solutions.
Market Positioning: The pace at which the new platform can capture market share in the competitive biopharma software space.